Dover Declares Regular Quarterly Cash Dividend
Get Alerts DOV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1%
Revenue Growth %: +7.8%
Join SI Premium – FREE
DOWNERS GROVE, Ill., May 7, 2021 /PRNewswire/ -- The Board of Directors of Dover (NYSE: DOV) today declared a regular quarterly cash dividend of $0.495 (forty-nine and one-half cents) per share, payable on June 15, 2021, to shareholders of record as of May 28, 2021.
About Dover: Dover is a diversified global manufacturer and solutions provider with annual revenue of approximately $7 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Fueling Solutions, Imaging & Identification, Pumps & Process Solutions and Refrigeration & Food Equipment. Dover combines global scale, operational agility, world-class engineering capability and customer intimacy to lead the markets we serve. Recognized for our entrepreneurial approach for over 60 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what's possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under "DOV." Additional information is available at dovercorporation.com.
Investor Contact: | Media Contact: |
Andrey Galiuk | Adrian Sakowicz |
Vice President – Corporate Development | Vice President – Communications |
and Investor Relations | (630) 743-5039 |
(630) 743-5131 | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/dover-declares-regular-quarterly-cash-dividend-301286862.html
SOURCE Dover
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe
- CleanTech Issues Clarification Regarding Qualified Person Disclosure
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share